Tetrous Taps Veteran Ballard to Spearhead EnFix Commercial Offensive

LOS ANGELES, CA – March 24, 2026 – In a strategic move signaling an aggressive push into the U.S. orthopedic market, Tetrous, Inc. has appointed industry veteran Thurman Ballard as its new Vice President of Sales. The appointment tasks Ballard with leading the commercial expansion of the company's innovative EnFix® platform, a technology aimed at fundamentally changing how surgeons repair the critical junction between bone and tendon.

The hire brings more than 35 years of specialized experience in commercializing disruptive medical technologies to the young company. For Tetrous, a firm founded in 2019 with a sharp focus on solving one of orthopedics' most persistent challenges, Ballard's leadership is a critical component in translating promising clinical results into widespread surgical adoption. He will be responsible for building out the sales organization and driving the market penetration of EnFix implants, which are designed to promote true biological healing where other methods have often fallen short.

A Seasoned Leader for an Ambitious Goal

Thurman Ballard's career is a roadmap of successful product launches and sales leadership roles within the orthopedic and sports medicine sectors. His track record includes building and leading high-performing teams that have consistently delivered strong revenue growth for both established players and emerging innovators.

Prior to joining Tetrous, Ballard served as Vice President of Sales at Pristine Surgical, where he spearheaded the launch of a novel single-use endoscopic platform. His extensive résumé also includes key leadership positions at Tornier, where he was integral to the North American commercialization of the Aequalis Shoulder Prosthesis. He has also held senior sales roles at Conventus Orthopedics, Smith & Nephew Endoscopy, and Colson Associated Companies, including Acumed and MicroAire, giving him a deep and nuanced understanding of the market dynamics Tetrous aims to navigate.

The significance of this appointment was not lost on Tetrous's leadership. "We are thrilled to be able to attract someone with Thurman's extensive surgeon relationships and track record to our team," said Dr. Bradley Patt, PhD, CEO of Tetrous. "I am confident that he will have a positive impact on our visibility in the sports medicine market." Ballard's proven ability to introduce disruptive products to a discerning surgical community is seen as a perfect match for Tetrous’s groundbreaking technology.

Beyond Repair: The Science of Enthesis Reformation

At the heart of Tetrous's mission is the enthesis—the complex, transitional tissue that connects tendon to bone. Historically, surgical repair of this junction, particularly in high-demand areas like the rotator cuff, has been plagued by high failure rates, reported to be anywhere from 13% to as high as 94% in some studies. This is often because the body's natural response is to form weaker scar tissue rather than regenerating the original, highly organized enthesis structure.

Tetrous aims to solve this with its EnFix family of demineralized bone fiber (DBF) implants. Unlike traditional reinforcement materials, EnFix is a 100% biologic implant designed to act as an osteoinductive and osteoconductive scaffold. It initiates endochondral ossification, a process that mimics the natural embryologic development of the enthesis. The technology, exclusively licensed for sports medicine from TheraCell, an ISTO Biologics Company, uses patented methods to create fibers that preserve the bone's natural nanotopography, providing an ideal environment for cellular attachment and tissue regeneration. Preclinical studies in sheep have demonstrated the formation of strong, Sharpey-like fibers—the collagenous fibers that firmly attach tendon to bone—resulting in a biomechanically superior connection compared to control repairs.

Ballard himself highlighted this focus in his new role. "Tetrous is pioneering biologic solutions to optimize enthesis reformation and transform outcomes in bone-to-tendon healing," he stated. "It's all about the enthesis, and I'm proud to help bring this innovative approach to more orthopedic and sports medicine applications." His goal is to help surgeons leverage the technology to "reduce failure rates, accelerate recovery, and deliver better long-term results for patients."

Navigating a Dynamic and Competitive Market

Ballard joins Tetrous at a time of significant growth and opportunity within the sports medicine landscape. The global market, valued at over $6 billion, is projected to exceed $8 billion by 2027, fueled by an aging yet increasingly active population and a rising incidence of sports-related injuries. Within this space, the orthobiologics segment—which includes products like EnFix—is a particularly high-growth area as the clinical focus shifts from purely mechanical fixes to true biological regeneration.

However, the market is also intensely competitive, dominated by giants like Arthrex, Stryker, and Smith & Nephew. Tetrous's strategy relies on differentiating itself with a highly specialized, procedure-specific solution that addresses a clear unmet need. The company's strong intellectual property portfolio, with multiple issued patents, provides a crucial competitive moat.

Investor confidence in this strategy is robust. In March 2025, Tetrous closed an oversubscribed Series A financing round of $6.5 million. The funding, supported by strategic partners, management, and new investors, is earmarked for increasing market penetration, generating further clinical evidence, and expanding the applications of its technology. With an estimated total addressable market in the USA approaching $2 billion, the commercial opportunity is substantial.

From Rotator Cuff to Broader Horizons

Since its limited commercial release in June 2023, the EnFix platform has already seen promising uptake, with more than 400 grafts implanted in over 200 surgical cases across the United States and Australia. Surgeons have reported positive initial results, noting the implant's ease of integration into existing surgical workflows and observing healthier, thicker tendon tissue in postoperative MRI scans.

"We are excited to welcome someone with Thurman's depth of experience in sports medicine to Tetrous," said John Bojanowski, the company's Chief Commercial Officer. "He has a proven ability to build high-performing sales teams, and we believe his leadership will significantly strengthen our commercial efforts as we continue to establish a mission-driven organization and scale the business."

Initially focused on the challenging rotator cuff repair market, the clinical application of EnFix has rapidly expanded. Surgeons are now utilizing the technology for a diverse range of enthesis injuries, including proximal and distal biceps tenodesis, insertional Achilles tendinopathy, gluteus medius repair, and proximal hamstring reattachment. This expansion underscores the platform's versatility and the widespread nature of the clinical problem it addresses. With Ballard now at the commercial helm, Tetrous is poised to accelerate this expansion, bringing its vision for a new standard in bone-to-tendon healing to a much wider audience of surgeons and patients.